Olaparib-Loaded Iron Oxide Nanoparticles for the Transgenic Treatment of Triple-Negative Breast Cancer (TNBC): Integrating Targeted Therapy and MRI Imaging: A Review
نویسندگان
1 Tashkent State Technical University after named Islam Karimov, Tashkent, Uzbekistan
2 Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan
3 Department of Fruits and Vegetables at the Urganch State University, Uzbekistan
4 Samarkand State Medical University, Samarkand, Uzbekistan
5 Karakalpak State University named after Berdakh, Nukus,Uzbekistan
6 Department of Agronomy, Navoi State Mining and Technological University, Navoi, Uzbekistan
7 Samarkand State University named after Sharof Rashidov, Uzbekistan
8 Urgench Branch of Tashkent University of Information Technologies named after Muhammad al-Khwarizmi, Urganch, Uzbekistan
9 Alfraganus University, Tashkent, Uzbekistan
10 Fergana Medical Institute of Public Health, Fergana, Uzbekistan
11 Fergana Medical Institute of Public Health, Fergana, Uzbekistan
12 Department of Oncology and Hematology, National Children’s Medical Center, Tashkent, Uzbekistan
13 Tashkent Institute of Irrigation and Agricultural Mechanization Engineers, National Research University, Tashkent, Uzbekistan
doi
10.22052/JNS.2025.02.004چکیده
Triple-negative breast cancer (TNBC) remains one of the most aggressive and treatment-resistant subtypes of breast cancer, characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The lack of targeted therapies and high rates of relapse underscore the urgent need for innovative treatment strategies. Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has shown promise in BRCA-mutated and homologous recombination-deficient (HRD) TNBC, but its clinical utility is limited by poor bioavailability, systemic toxicity, and intrinsic resistance. Iron oxide nanoparticles (IONPs) offer a transformative platform to address these challenges by enabling tumor-targeted drug delivery and non-invasive magnetic resonance imaging (MRI). This review explores the design, development, and theranostic potential of Olaparib-loaded IONPs, emphasizing their dual functionality as therapeutic carriers and imaging contrast agents. Preclinical advancements, clinical translation challenges, and future directions are critically analyzed to provide a comprehensive perspective on bridging nanomedicine with precision oncology in TNBC.
